Fig. 5

The combination effect of GX 15–070 and cisplatin or doxorubicin in NB cells. 5X10³ SK-N-DZ and IGR-NB8 cells treated with GX 15–070 IC₅₀ calculated at 48 h post-treatment and different concentrations of cisplatin (a) and doxorubicin (b) ranging from 0.015 to 75.0 μg/mL and from 0.005 to 5.0 μg/mL respectively during 48 h. Viability was calculated as the percentage of living cells in treated cultures compared to those in control cultures. Each value represents the mean ± SEM (n = 3). Western blotting showed cleaved caspase-3 (c) and LC3I and LC3II expression (d) in SK-N-DZ and IGR-NB8 cells treated with 0.05 μM GX 15–070 or in combination with cisplatin. (e) Synergistic effect of GX 15–070 and cisplatin or doxorubicin on cell growth in vitro. Cells were treated with increasing concentrations of drugs either alone or concurrently at their equipotent molar ratio and combination indices (CIs) calculated by the method of Chou and Talaly